Posts Tagged ‘prostate cancer early detection’
Our prostate cancer team has big news from the Prostate Active Surveillance Study (PASS) – a new publication in JAMA Oncology!
October 7, 2020
Our prostate cancer team has more than a decade of experience working remotely from various institutions. During the time of the pandemic, the team has moved forward on important fronts.
Big News –PASS has a new publication in JAMA Oncology! A scientific paper was recently published in the premiere publication JAMA Oncology: The Journal of the American Medical Association. JAMA is a rigorously peer-reviewed medical journal. The principal investigator Matthew R. Cooperberg is on Canary’s Prostate Active Surveillance Study (PASS) team. Many familiar names from the team are seen on the study. The study shows an important way of determining risk assessment that can aid in deciding how often to monitor and other decisions. To hear an interview with Dr. Cooperberg, click here:
Tissue Microarray. The team studies the progression of prostate cancer using high-through analysis of multiple cases. Work in this area during the pandemic has included the review of new proposals and project progress from partners, including ones from Austria and Canada. The work has included data analysis, correcting missing data, and arranging tissue shipment.
PASS Central Review. Decisions have been made on reviewing cases.
Meetings and communications. The prostate team has been disciplined in meeting remotely and communicating long distances since it’s formation in 2006. A group meeting was held in June and follow up ensued. Additionally, their annual November in-person meeting has been approved to move to a virtual format.
Enrolling men. PASS enrolls men to keep a steady level of patients as some men rotate out of the program, 2000 being the current number of enrollees. Enrollment is on hold due to the pandemic.
Other action of the Prostate Team include:
- Reviewing new proposals for Canary TMA (pathology)
- Progress on approved projects for Canary TMA (pathology) has been made with data having been submitted from a number of groups and a shipment of tissue samples having been coordinated to an international partner.
- Concordance project for PASS central review (pathology), coordinated decision making on review of cases.
- Papers: read and commented on meeting submissions and manuscripts in progress.
- Administrative: we have held an all-team PASS and prostate pathology group meetings, distributed notes & action items. Plan approved to move November 20 meeting to virtual format.
Canary’s Prostate Active Surveillance Study (PASS) receives $6.7M NCI grant to support growth of the multi-center study!
December 2, 2019
PASS was established in 2008 with funding from the Canary Foundation, demonstrating how we invest in promising early research!
“PASS was launched with six participating centers in 2008,” said PASS Deputy Director Dr. Lisa Newcomb, a Hutch cancer prevention researcher. “With this grant, we’ll be up to 11 sites. Fred Hutch is the centralized repository — specimens are sent to the Hutch from all the sites — and we have procedures for sharing the data and the specimens among the group [members] and with other researchers.”
The grant is designed to support the infrastructure of the PASS cohort, including the collection of follow-up data, management of the database and management of the biospecimen repository.
PASS participants are all early-stage prostate cancer patients who chose active surveillance, not immediate surgery or radiation, to manage their cancer. In active surveillance, patients receive regular PSA (prostate-specific antigen) testing, biopsies and digital-rectal exams to monitor whether the cancer grows or becomes more aggressive.
According to research, more than 30% of men have slow-growing prostate cancer and won’t necessarily benefit from radical treatments that can cause debilitating side effects such as urinary incontinence and impotence. Data from patients with early-stage prostate cancers who choose active surveillance can provide key insights into who’s most at risk from their cancers, and when.
Using the cohort for risk-prediction modeling, Newcomb said, could help “determine who either harbors or will progress to a bad cancer, which cancers are aggressive and which really aren’t.”
“We want to help identify the men who can go home and not worry about their cancer. We’re looking at both ends of the spectrum — making active surveillance less active and identifying the people who will benefit from treatment early.” – Dr. Lisa Newcomb
“We are thrilled,” said Newcomb regarding the transition from Canary Foundation support to NCI funding.
Fred Hutch has had a longstanding relationship with the Canary Foundation and has been the recipient of many grants from the foundation powering work in early detection. The fifth floor of Fred Hutch’s Arnold Building, home to its Public Health Sciences Division, is named for the foundation.
At present, participating sites for PASS include the University of California, San Francisco; Stanford University; Emory University; Beth Israel Deaconess Medical Center/Harvard Medical School; University of Michigan; University of Texas Health Science Center, San Antonio; Eastern Virginia Medical School; Veterans Affairs Puget Sound Health Care System; University of Washington and University of British Columbia.
Interested in accessing Canary PASS Active Surveillance Risk Calculators? The PASS Risk Calculators provide estimates of how likely a man is to have more aggressive cancer in the future. These tools are intended to be useful for clinicians and their patients as they determine optimal methods of active surveillance. Access the risk calculators: https://canarypass.org/pass-risk-calculator/
To read the full article by Diane Mapes, a staff writer at Fred Hutchinson Cancer Research Center, please go to: https://www.fredhutch.org/en/news/center-news/2019/11/prostate-cancer-study-nci-funding-grant.html
February 4, 2014
In honor of World Cancer Day, we are officially opening registration for the Canary Challenge 2014. Register for the ride now for $25 until March 31.
World Cancer Day is a chance to raise our collective voices in the name of improving general knowledge around cancer and dismissing misconceptions about the disease. For Canary, we’re emphasizing the need for more cancer early detection research, awareness, and advocacy. A great way to get involved is by participating in the Canary Challenge 2014.
This amazing one-day cycling event is about to get bigger and better than ever. The event will be hosted at HP’s campus in Palo Alto on Hanover St. We’re aiming high this year with a goal of raising $1.5 million, recruiting 150 teams and over 1,500 riders. This year’s ride will benefit the Canary Center at Stanford, supporting the researchers, scientists and doctors who are dedicated to cancer early detection. Register now and be part of the pioneering edge of cancer early detection research!
January 29, 2014
The beginning of the year presents a cue to reflect on the successes of the previous year, and look forward to goals for the coming months. We’re delighted to announce progress with our research that has tremendous implications for future innovations, as well as our ambitions for the Canary Challenge 2014.
New technologies always evoke excitement and anticipation. Here at Canary, if a scientist wants to use a new technology to advance or improve the ways we detect cancer tumors early, we are all for it. Enhanced ultrasound using microbubble technology is one of these technologies.
This technology will change the way doctors view tumors. Microbubbles are miniature gas bubbles, mostly containing oxygen or air, which can be uniformly suspended in a liquid such as blood. Due to their size, they can pass through even the smallest of blood vessels and therefore are commonly used together with medical ultrasound imaging. As effective vehicles for highlighting blood in ultrasound images, Canary scientists use microbubbles as a contrast agent to view cancer tumors. Our clinical trials in Rome with women who have ovarian cancer have produced great results. Here in the US, we anticipate replicating microbubble technology for applications with breast cancer, prostate and pancreatic cancer.
We also value and actively seek out key partnerships, whether academic or industry. Soon we’ll announce a partnership with Genomic Health Inc. in the area of prostate cancer. We’re in talks with MD Anderson in Houston to help with coordinating a national multi-institutional lung cancer study.
We have great plans for our largest fundraising event, the Canary Challenge, which is about to get bigger and better than ever. Mark your calendar now for September 27, 2014. Register now for $25 until March 31. The event will be hosted at HP’s campus in Palo Alto on Hanover St. We’re aiming high this year with a goal of raising $1.5 million, recruiting 150 teams and over 1,500 riders. This year’s ride will benefit the Canary Center at Stanford, supporting the researchers, scientists and doctors who are dedicated to cancer early detection. Come be a part of an amazing one-day cycling event!
We’re pleased to announce that we will again be partnering with women’s pro cycling team extraordinaire, the Vanderkittens, who will host monthly training rides for Canary Challenge riders. Hani Juha, a cyclist and great coach, of Menlo Bike Club will also offer weekly training rides, an annual training program, as well as monthly clinics. We invite anyone and everyone in the Canary community to take advantage of these tailored experiences to brush up on their skills in time for the event.
What are your hopes and dreams for cancer early detection research at Canary Foundation? Let us know in the comments below!
December 4, 2013
Canary Foundation’s progress continues to be on a rapid path. Through prestigious partnerships, research, and clinical trials with quantifiable results, Canary Foundation is funding early detection research that will save lives and permanently change the landscape of cancer diagnostics. People like you have made this progress possible.
In 2013, our partnership with Stanford University expanded and we moved into our new state-of-the-art Canary Center at Stanford to continue our work realizing early detection solutions.
We are pleased to share a new video featuring our high points. We thought this was a great way to reflect on key ideas Canary was founded upon that have become reality. We invite you to view our 5-minute Canary Foundation video!
When you and your family make giving decisions this holiday, we ask that make cancer early detection a priority. Please give generously.
November 14, 2013
About one man in six will be diagnosed with prostate cancer in his lifetime. Most men diagnosed with prostate cancer will not die from it. With screening, we’re doing better at identifying prostate cancer early. But now, the clinical question is: with a prostate cancer diagnosis, do we treat, or is treatment not necessary?
Treating prostate cancer when it’s not necessary exposes men to potential side effects—including incontinence and impotence– of aggressive treatment like surgery. This is known as overtreatment. We need better tools to differentiate aggressive prostate cancer from non-aggressive prostate cancer to guide these decisions.
In 2007, the Canary prostate team decided to focus on this important clinical question. How will we distinguish lethal from non-lethal prostate cancer? Identifying the difference early on will save lives. New tools will also help end unnecessary biopsies and overtreatment.
By 2008, the team launched a clinical trial called PASS, the Prostate Active Surveillance Study. Men with early stage, localized, low-risk prostate cancer can enroll and have their cancer closely monitored for signs of progression. This process is called active surveillance. The trial’s goal is to manage low-risk prostate cancer through active surveillance while identifying markers to distinguish non-aggressive prostate cancer from potentially lethal disease.
The PASS trial has been running smoothly, and in October 2013, the PASS Trial reached another major milestone when the 1,000th man was enrolled in the trial.
We are so grateful for Canary Foundation supporters, who provided funding early on for this work. They recognized that the project was underfunded and important. We’re also extremely thankful to the men who participated in the trial for contributing tens of thousands of samples to prostate cancer early detection research. Thank you!
November 7, 2013
Recently, Canary Foundation and Stanford embarked on a collaboration with the MD Anderson Cancer Center, working together on a large-scale initiative to improve the screening process of lung cancer for earlier detection of this lethal disease.
The Canary lung cancer team leader, Dr. Sam Hanash, was recruited to the MD Anderson Cancer Center, which launched an ambitious Moon Shots Program aimed at rapidly and significantly reducing mortality in several major cancers. Lung cancer is currently the leading cause of cancer deaths.
As part of Moon Shots program, lung cancer physicians and researchers are initiating a screening study to improve screening for lung cancer. The goal is to recruit 10,000 individuals in the U.S., and to partner with international sites, including China and Germany, to conduct studies with an additional 10,000 patients. Canary will be joining forces with MD Anderson, combining CT scan technology and biomarker research to better interpret screening results.
These clinical trials represent the next phase of Canary research, taking the progress we’ve made in the lab and testing it in a larger clinical setting.
October 29, 2013
Photo: The clinical trial coordinators for the Canary Prostate Active Surveillance Study (PASS) accept the 2013 Canary Award on behalf of the Canary Prostate Team.
Dr. Dianne Miller was presented with the award for her team’s success in promoting adoption of ovarian cancer prevention programs throughout the Canadian province of British Columbia. Because lethal ovarian cancer often originates in fallopian tubes, their removal can prevent the development of ovarian cancer, potentially reducing the incidence by 50% or more. Since the advent of the British Columbia educational campaign in September 2010, clinics across the province have seen a practice shift toward removal of fallopian tubes during common gynecological surgeries (such as hysterectomy and tubal ligation), thanks to the efforts of Dr. Miller’s team.
The Canary Prostate team was presented with the Canary Award for the team’s success in meeting or exceeding all of its major milestones in the Prostate Active Surveillance Study (PASS) clinical trial. Earlier in the month of October, 2013, the PASS trial celebrated reaching another major milestone, as the 1,000th participant was enrolled in the trial. The trial’s goal is to manage low-risk prostate cancer through active surveillance while identifying markers to distinguish non-aggressive prostate cancer from potentially lethal disease.
Congratulations to both teams for all their hard work, and to all the Canary teams who work tirelessly to develop research and solutions to make accessible cancer early detection a reality.
October 7, 2013
In the United States, it is estimated that there will be 232,340 new breast cancer cases and 39,620 breast cancer mortalities in 2013. 1 in 8 women will be diagnosed with breast cancer during their lifetime. Despite the widespread use of mammography, the technology is limited as many cancers are missed and conversely many women undergo biopsies and surgeries of benign or non-aggressive tumors.
Canary Foundation is supporting a Breast Cancer Early Detection Initiative focused on finding blood-based and imaging biomarkers to improve the current state of breast cancer early detection. The vision of the blood work is to distinguish women with benign versus malignant tumors, and to identify the aggressive, hard to detect, breast cancers. The vision of the imaging work is to detect breast cancer at the earliest stages, when the tumors are very small.
Canary is committed to funding safe, efficient, cost effective tests for cancer early detection.
October 3, 2013
This past weekend, 800 cyclists converged at VMware village to kick off Canary Challenge 2013, a great increase over the number of riders from last year! Over $800,000 was raised to benefit cancer research at the Stanford Cancer Institute and Canary Center for Cancer Early Detection at Stanford.
There were a total of 78 teams participating, with over 120 volunteers cheering, manning registration, and passing out drinks and snacks to replenish riders along the route. Most incredible was the great energy at the event – participants’ dedication and commitment to the cause was palpable, and the celebratory air when cyclists returned triumphant from their rides was electric.
We loved when riders stopped by the social photo booth to show us “#WhyIRideCanary”. Everyone who contributed to the event did so because they were inspired by the need for cancer early detection research. It was incredible to hear their stories – a great reminder of why we ride.
A great thank you to all the riders, sponsors, volunteers and staff who came together on September 28 to make this ride such a great success. Ride on, Canary Challenge participants! Save the date for next year: September 27, 2014!